HIGHLIGHTS
- who: Alex Howard from the Liverpool University Liverpool, Liverpool, BX, UK have published the research: CON: Serum biomarker monitoring should not replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy, in the Journal: (JOURNAL)
SUMMARY
Individuals undergoing systemic anti-cancer therapy (SACT) for acute leukaemia (AL) are at high risk of developing invasive fungal disease (IFD), a group of infections associated with sig nificant morbidity and mortality. Increased up take of the serum fungal biomarkers galactomannan (GM) and 1,3-β-D-glucan (BDG) in the diagnosis of IFD . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.